This real-time learning process was carried out in order to identify the gaps and needs within World Vision’s current Ebola Virus Disease (EVD) response in Sierra Leone and to inform World Vision on how other surrounding countries (specifically those with national offices such as Mali, Ghana, Nig...er, Mauritania, Senegal and Chad) should prepare for a possible Ebola outbreak.
more
Chapter 8, Prison and Health, published
The document contains preliminary report on all aspects of WHO’s response in the Ebola outbreak. WHO Member States will discuss the report at the sixty-eighth World Health Assembly.
Policy Brief
November 2014
The report will describe how the Ebola Response MPTF, which has attracted contributions from 38 Member States, one business and many individuals, has offered a transparent and strategic tool to support the Ebola response. As of 31 January 2015, the Fund had total pledges amounting to US$142 million,... out of which US$132 million have been deposited
more
Summary of research into the consequences of the Ebola outbreak for children and communities in Liberia and Sierra Leone
This study describes the range of impacts that Ebola has had on children and families in Liberia and Sierra Leone, looking beyond the immediate health effects
An international field study by African and German Theologicans and health workers
Reproduced by CHAL (Chrisitan Health Association Liberia) 3 October 2014
An Independent Report
of the West Africa Commission on Drugs
An international field study by African and German theologicans and health workers.
Interim emergency guidelines
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more